重组组织型纤溶酶原激活物联合亚低温治疗急性脑梗死36例分析

Efect of recombinant tissue-type plasminogen activator combined with mild hypothermia for acute cerebral infarctions

目的 评价重组组织性纤溶酶原激活物（rt-PA）联合亚低温治疗急性脑梗死的临床疗效. 方法 符合人选标准的72例患者分为两组：对照组仅接受rt-PA溶栓治疗,联合治疗组在rt-PA溶栓治疗的同时加用亚低温治疗.神经功能缺失状态由欧洲卒中量表（ESS）评价. 结果 发病6 h内给予溶栓治疗的联合治疗组患者在溶栓后3 d的ESS评分显著高于对照组患者.发病6～12 h给予溶栓治疗的联合治疗组患者在溶栓后24 h的ESS评分显著高于对照组患者. 结论 rt-PA联合亚低温治疗的效果优于单用溶栓治疗,联合治疗急性闭塞性脑血管病安全有效.

Objective To evaluate the efficacy of recombinant tissue-type plasminogen activator（rt-PA）and mild hypothermia for acute cerebral infarctions. Methods 72 patients consistent with the inclusion criteria were randomly divided into 2 groups,hypothermia group receivied rt-PA combined with mild hypothermia and control group receiving rt-PA only.Neurological functions was evaluated with European Stroke Scale（ESS）. Results As intravenous thrombolytic therapy within 6h after the onset,the ESS scores examined 3 days after thrombolysis in hypothermia group was significantly higher than those in control group.As intravenous thrombolytic therapy during 6h to 12h after the onset,the ESS scores of hypothermia group increased more significantly from 24h after thrombolysis than those in control group. Conclusion ft-PA combined with mild hypothermia was more effective than rT-PA only for acute cerebral infarctions,which was effective and relatively safe in the treatment of acute ischemic cerebral vascular disease.